510(k) K233606
K233606 is an FDA 510(k) premarket notification submitted by Biokit, S.A. for the device "ADVIA Centaur EBV-VCA IgM". The FDA issued a decision of Substantially Equivalent on August 7, 2024. The device falls under product code LSE (Epstein-Barr Virus, Other), a Class I device regulated under 21 CFR 866.3235. Biokit, S.A. has at least 10 other 510(k) clearances on record.
Clearance Details
- Decision
- SESE (Substantially Equivalent)
- Decision Date
- August 7, 2024
- Date Received
- November 9, 2023
- Clearance Type
- Traditional
- Expedited Review
- No
- Third Party Review
- No
Device Classification
- Device Name
- Epstein-Barr Virus, Other
- Device Class
- Class I
- Regulation Number
- 866.3235
- Review Panel
- MI
- Submission Type